Download PDF
Semin Thromb Hemost 2013; 39(07): 767-771
DOI: 10.1055/s-0033-1356574
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Challenges in the Management of Hemophilia B with Inhibitor

Angelika Batorova
1   Department of Hematology and Transfusion Medicine, National Hemophilia Center, University Hospital, Bratislava, Slovakia
,
Anna Morongova
1   Department of Hematology and Transfusion Medicine, National Hemophilia Center, University Hospital, Bratislava, Slovakia
,
Giuseppe Tagariello
2   Haemophilia Centre and Haematology Department, Castelfranco Veneto Hospital, Castelfranco Veneto (TV), Italy
,
Denisa Jankovicova
1   Department of Hematology and Transfusion Medicine, National Hemophilia Center, University Hospital, Bratislava, Slovakia
,
Tatiana Prigancova
1   Department of Hematology and Transfusion Medicine, National Hemophilia Center, University Hospital, Bratislava, Slovakia
,
Julia Horakova
3   Department of Hematological Oncology and Bone Marrow Transplantation, Children's University Hospital, Bratislava, Slovakia
› Author Affiliations
Further Information

Publication History

Publication Date:
10 September 2013 (online)

    Permissions and Reprints

Abstract

Development of factor IX (FIX) inhibitor is a rare but challenging complication in hemophilia B. In addition to inefficacy of specific replacement therapy, FIX inhibitors increase morbidity due to serious allergic reactions/anaphylaxis upon treatment with FIX. Limited experience with immune tolerance induction (ITI) shows a high risk of nephrotic syndrome development and poor ITI outcomes. Recently, immunomodulation therapy has been used in ITI regimens in hemophilia B; however, relevant guidelines for ITI in hemophilia B are still lacking. We describe a 7-year-old hemophilia B patient with “null” mutation Arg29 stop who underwent surgery and massive transfusion therapy in the neonatal period and developed an FIX inhibitor after consecutive 20 exposures to FIX concentrate. At the age of 6 years, a high-dose ITI was commenced combined with immunomodulation therapy including rituximab, dexamethasone, and intravenous immunoglobulin. Allergic reactions that occurred in the third week of ITI were resolved by premedication with antihistamines and continued immunomodulation protocol without any need for ITI interruption. Inhibitor was negative from week 10; however, doses of FIX continued unchanged until pharmacokinetic criteria for success were met at month 9 of ITI. One year after the start of ITI, the patient started regular prophylaxis with FIX 41 IU/kg three times a week. No further allergic reactions or any signs of nephrotic syndrome have occurred.

Keywords

hemophilia B - FIX inhibitor - allergic reactions - immune tolerance induction - immunomodulation therapy - rituximab
 

  • References

  • 1 Astermark J, Lacroix-Desmazes S, Reding MT. Inhibitor development. Haemophilia 2008; 14 (Suppl. 03) 36-42
    PubMedGoogle Scholar
  • 2 DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13 (Suppl. 01) 1-22
    PubMedGoogle Scholar
  • 3 DiMichele DM. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138 (3) 305-315
    CrossrefPubMedGoogle Scholar
  • 4 Puetz J, Soucie JM, Kempton CL, Monahan PE ; Hemophilia Treatment Center Network (HTCN) Investigators. Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database. Haemophilia 2013; (e-pub ahead of print). doi:10.1111/hae.12229
    PubMedGoogle Scholar
  • 5 Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12 (Suppl. 06) 15-22
    PubMedGoogle Scholar
  • 6 Coppola A, Margaglione M, Santagostino E , et al; AICE PROFIT Study Group. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7 (11) 1809-1815
    CrossrefPubMedGoogle Scholar
  • 7 Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 2009; 35 (8) 723-734
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Coppola A, Santoro C, Tagliaferri A, Franchini M, DI Minno G. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia 2010; 16 (Suppl. 01) 13-19
    PubMedGoogle Scholar
  • 9 Hay CR, DiMichele DM ; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119 (6) 1335-1344
    CrossrefPubMedGoogle Scholar
  • 10 Collins PW, Chalmers E, Hart DP , et al; UK Haemophilia Centre Doctors. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). Br J Haematol 2013; 160 (2) 153-170
    CrossrefPubMedGoogle Scholar
  • 11 Ewenstein BM, Takemoto C, Warrier I , et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89 (3) 1115-1116
    PubMedGoogle Scholar
  • 12 DiMichele DM, Kroner BL ; North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87 (1) 52-57
    PubMedGoogle Scholar
  • 13 Warrier I. Inhibitors in hemophilia B. In: Lee CA, Berntorp E, Hoots WK, , eds. Textbook of Hemophilia. Oxford and Malden, MA: Blackwell Publishing; 2005: 97-100
    CrossrefGoogle Scholar
  • 14 Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15 (5) 1027-1031
    CrossrefPubMedGoogle Scholar
  • 15 DiMichele DM. Immune tolerance in haemophilia: the long journey to the fork in the road. Br J Haematol 2012; 159 (2) 123-134
    CrossrefPubMedGoogle Scholar
  • 16 Dioun AF, Ewenstein BM, Geha RS, Schneider LC. IgE-mediated allergy and desensitization to factor IX in hemophilia B. J Allergy Clin Immunol 1998; 102 (1) 113-117
    CrossrefPubMedGoogle Scholar
  • 17 Shibata M, Shima M, Misu H, Okimoto Y, Giddings JC, Yoshioka A. Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Haemophilia 2003; 9 (3) 269-271
    CrossrefPubMedGoogle Scholar
  • 18 Curry NS, Misbah SA, Giangrande PLF, Keeling DM. Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction. Haemophilia 2007; 13 (3) 328-330
    CrossrefPubMedGoogle Scholar
  • 19 Chuansumrit A, Moonsup Y, Sirachainan N, Benjaponpitak S, Suebsangad A, Wongwerawattanakoon P. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate. Blood Coagul Fibrinolysis 2008; 19 (3) 208-211
    CrossrefPubMedGoogle Scholar
  • 20 Cross DC, Van Der Berg HM. Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors. Haemophilia 2007; 13 (1) 111-114
    CrossrefPubMedGoogle Scholar
  • 21 Wermes C, von Depka Prondzinski M, Welte K, Sykora K-W. New strategy for the treatment of factor IX inhibitors in severe haemophilia B. Blood 2000; 96: 647 (abstract)
    PubMedGoogle Scholar
  • 22 Klarmann D, Martinez Saguer I, Funk MB , et al. Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. Haemophilia 2008; 14 (1) 44-49
    PubMedGoogle Scholar
  • 23 Mathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125 (3) 366-368
    CrossrefPubMedGoogle Scholar
  • 24 Alexander S, Hopewell S, Hunter S, Chouksey A. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis. J Pediatr Hematol Oncol 2008; 30 (1) 93-95
    CrossrefPubMedGoogle Scholar
  • 25 Beutel K, Hauch H, Rischewski J, Kordes U, Schneppenheim J, Schneppenheim R. ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor. Hamostaseologie 2009; 29 (2) 155-157
    PubMedGoogle Scholar
  • 26 Barnes C, Davis A, Furmedge J, Egan B, Donnan L, Monagle P. Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX. Haemophilia 2010; 16 (5) 840-841
    CrossrefPubMedGoogle Scholar
  • 27 Thorland EC, Drost JB, Lusher JM , et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999; 5 (2) 101-105
    CrossrefPubMedGoogle Scholar
  • 28 Castaman G, Bonetti E, Messina M, Morfini M, Rocino A, Scaraggi FA, Tagariello G . and Italian Association of Hemophilia Centers. Inhibitors in haemophilia B: the Italian experience. Haemophilia 2013; (e-pub ahead of print). doi:10.1111/hae.12158
    PubMedGoogle Scholar
  • 29 Sawamoto Y, Shima M, Yamamoto M , et al. Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates. Thromb Res 1996; 83 (4) 279-286
    CrossrefPubMedGoogle Scholar
  • 30 Verghese P, Darrow S, Kurth MH, Reed RC, Kim Y, Kearney S. Successful management of factor IX inhibitor-associated nephrotic syndrome in a hemophilia B patient. Pediatr Nephrol 2013; 28 (5) 823-826
    CrossrefPubMedGoogle Scholar
  • 31 Nagel K, Laudenbach L, Rivard GE, Jardine L, Chan AK, Pai MK. Immune tolerance induction for a patient with factor IX inhibitors—a case report. Haemophilia 2011; 17 (2) 315
    CrossrefPubMedGoogle Scholar
  • 32 Klukowska A, Laguna P, Waleszkiewicz-Majewska B , et al. Successful immune tolerance induction in two boys with haemophilia B and inhibitory antibodies. Haemophilia 2012; 18 (3) e67-e69
    CrossrefPubMedGoogle Scholar
  • 33 Poon MC. Pharmacokinetics of factors IX, recombinant human activated factor VII and factor XIII. Haemophilia 2006; 12 (Suppl. 04) 61-69
    PubMedGoogle Scholar
  • 34 Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 2002; 87 (3) 431-435
    PubMedGoogle Scholar